5 Prescription Drugs Selling Like Hot Cakes

November 10, 2014 12:21 AM

15 0

Considering that 90% of prescription drugs being developed by biotechnology companies will fail during clinical trials, it can be tough to know which biotech stocks to seize upon and which stocks to shun. Instead of focusing on unproven companies offering more promise than profit, a better investment strategy may be concentrating on biotech companies like these five that are already marketing fast growing treatments.

Passing the baton Gilead Sciences ' Sovaldi has been a runaway success since launching last December. The drug is the fastest medicine to ever reach the $1 billion blockbuster sales mark and with more than $8 billion in sales during its first nine months on the market, Sovaldi is flirting with being...

Read more

To category page